<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
UBS upgraded the Biogen’s stock to “buy” from “neutral” and Bernstein raised its rating to “outperform.” Both firms base their moves on the potential sales bump from the FDA’s approval this week of the biotech’s Alzheimer’s treatment.
...read full article on CNBC Television
